Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Sartorius Stedim Biotech S.A.

Start price
Target price
Perf. (%)
€328.00
20.02.22
€400.00
20.02.23
1.01%
21.02.23

Could be worthwhile Investment >10% per year
Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
20.02.22
€13.00
20.02.23
-
17.03.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€6.85
20.02.22
-
20.02.23
-14.37%
05.03.22

Could be very worthwhile Investment >20% year
Orpea Nom.

Start price
Target price
Perf. (%)
€36.36
19.02.22
€32.00
19.02.23
-5.42%
05.03.22

Risky Investment
buy
Valbiotis

Start price
Target price
Perf. (%)
€6.09
19.02.22
-
19.02.23
-18.39%
05.10.22

Could be worthwhile Investment >10% per year
buy
Evofem Biosciences Inc.

Start price
Target price
Perf. (%)
€6.08
17.02.22
€12.00
17.02.23
2.02%
21.02.22

Could be very worthwhile Investment >20% year
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€17.02
16.02.22
-
16.02.23
-10.26%
19.02.22

Could be worthwhile Investment >10% per year
buy
Poxel S.A.

Start price
Target price
Perf. (%)
€4.07
15.02.22
€5.00
15.03.22
-25.36%
20.02.22

Could be worthwhile Investment >10% per year
buy
Innate Pharma

Start price
Target price
Perf. (%)
€3.24
10.02.22
€3.80
10.02.23
-4.81%
11.02.23

Could be worthwhile Investment >10% per year
Canopy Growth Corp

Start price
Target price
Perf. (%)
€7.83
09.02.22
-
09.02.23
-12.11%
18.02.22

Probably not worthwhile Investment
buy
Avid Bioservices Inc

Start price
Target price
Perf. (%)
€18.30
09.02.22
€20.00
09.03.22
-7.10%
10.03.22

Could be worthwhile Investment >10% per year
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€15.70
07.02.22
-
07.02.23
-60.50%
19.09.22

Could be worthwhile Investment >10% per year
Very high cyclical dependencies
Orpea Nom.

Start price
Target price
Perf. (%)
€34.38
06.02.22
€31.00
06.02.23
5.76%
19.02.22

Risky Investment
buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€6.22
06.02.22
-
06.02.23
-15.28%
20.02.22

Risky Investment
buy
Molecular Templates Inc.

Start price
Target price
Perf. (%)
€2.53
06.02.22
-
06.02.23
-8.76%
20.02.22

Could be very worthwhile Investment >20% year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.03
05.02.22
€20.00
05.02.23
-57.41%
06.02.23

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Good culture
Could be very worthwhile Investment >20% year
buy
BiondVax Pharmaceuticals Ltd ADR

Start price
Target price
Perf. (%)
€0.40
04.02.22
-
-
06.02.22

Risky Investment
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€56.78
04.02.22
€46.00
04.02.23
18.67%
13.10.22

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
buy
Theranexus

Start price
Target price
Perf. (%)
€3.18
04.02.22
€36.00
04.02.23
-41.98%
05.02.23

Could be worthwhile Investment >10% per year
buy
Sangamo Therapeutics Inc.

Start price
Target price
Perf. (%)
€5.04
02.02.22
-
02.02.23
-4.33%
06.02.22

Risky Investment
buy
Clovis Oncology Inc.

Start price
Target price
Perf. (%)
€1.66
02.02.22
-
02.02.23
-3.83%
06.02.22

Risky Investment
buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€147.00
01.02.22
€180.00
01.08.22
-3.71%
01.08.22

Could be very worthwhile Investment >20% year
Standard Investments for future growth
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€87.29
01.02.22
-
01.02.23
-88.23%
02.02.23

Could be worthwhile Investment >10% per year
Fair valuation
Revenue growth >5% per year expected
Standard Investments for future growth
buy
Innate Pharma

Start price
Target price
Perf. (%)
€3.51
01.02.22
€4.15
01.02.23
-7.69%
10.02.22

Could be worthwhile Investment >10% per year
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€5.39
30.01.22
€4.00
30.01.23
-10.83%
14.03.22

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year